This Wauwatosa startup says it discovered a better test for certain blood clotting diseases: The Pitch
Retham Technologies LLC has developed a test for heparin-induced thrombocytopenia (HIT) and related blood clotting disorders that is faster and more accurate than the ones currently on the market. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 15, 2021 Category: Pharmaceuticals Authors: Teddy Nykiel Source Type: news

Interim Clinical Commissioning Policy: Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic,NHS England,updated 6th October 2021
The policy is for thrombopoietin receptor agonists as first line therapy for new or relapsed acute immune thrombocytopenia in adults and children over the age of 1 year. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 6, 2021 Category: Consumer Health News Source Type: news

Twitter now "fact checking" OBITUARIES of people killed by vaccines in effort to bury vaccine-induced deaths
(Natural News) When 37-year-old Jessica Berg Wilson of Seattle passed away from covid vaccine-induced thrombotic thrombocytopenia (VITT) on September 7, her family published a loving obituary that was ripped to shreds by the “fact checkers” at Twitter. According to reports, Jack Dorsey’s empire disgraced Wilson’s life and disrespected her family by claiming that Wilson’s obituary... (Source: NaturalNews.com)
Source: NaturalNews.com - October 6, 2021 Category: Consumer Health News Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), British Society for Haematology
Updated Guidance on Management. Version 2.2 31 August 2021 (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 13, 2021 Category: Consumer Health News Source Type: news

Mycophenolate Mofetil Treats Immune Thrombocytopenia
Fewer treatment failures and greater response, but poorer quality of life seen when added to a glucocorticoid for first - line treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news

Mycophenolate Mofetil Treats Immune Thrombocytopenia
THURSDAY, Sept. 2, 2021 -- For adults with immune thrombocytopenia, the addition of mycophenolate mofetil to a glucocorticoid for first-line treatment is associated with fewer treatment failures and higher response rates than glucocorticoid-only... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2021 Category: Pharmaceuticals Source Type: news

What are Some of the Complications of Short Bowel Syndrome?
Discussion Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in neonates. Mortality rates are from 0-45% depending on infant weight and gestation with more premature and smaller infants having greater mortality. NEC usually occurs in premature infants but it also occurs in term infants. The etiology is unknown but is probably multifactorial with ischemia and/or reperfusion playing some role. There are ‘outbreaks’ of NEC but no causative organism has been identified. Regardless of the originating cause, inflammation of the intestine and release of inflammatory mediators cause...
Source: PediatricEducation.org - August 30, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Features of Vaccine-Induced Thrombotic Syndrome Studied
THURSDAY, Aug. 12, 2021 -- Mortality seen in association with vaccine-induced immune thrombocytopenia and thrombosis (VITT) after the first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) is increased for those with cerebral venous sinus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2021 Category: Pharmaceuticals Source Type: news

Coronavirus disease 2019 (COVID-19) Updates, BMJ Best Practice
1. NICE publishes new guidance on vaccine-induced immune thrombocytopenia and thrombosis. 2. FDA authorises casirivimab/imdevimab for prevention of COVID-19. 3. EMA warns of Guillain-Barre syndrome with Janssen COVID-19 vaccine. 4. EMA authorises use of Moderna COVID-19 vaccine in young people aged 12 to 17 years. 5. CDC warns that vaccinated people with breakthrough infections can spread the Delta variant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news

European PRAC updated safety issues with Janssen COVID-19 Vaccine, EMA
PRAC has recommended including immune thrombocytopenia, dizziness and tinnitus as adverse reactions, and to re-classify'thrombocytopenia', currently an important potential risk, as an important identified risk. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news

Aussie woman dies after receiving first AstraZeneca vaccine dose
(Natural News) A 34-year-old woman in Australia died on Aug. 4 after she received her first Wuhan coronavirus (COVID-19) vaccine dose from AstraZeneca. Officials said the New South Wales (NSW) resident died of thrombosis with thrombocytopenia syndrome (TTS), which involved blood clots and low blood platelet count. The 34-year-old was the seventh person who died... (Source: NaturalNews.com)
Source: NaturalNews.com - August 9, 2021 Category: Consumer Health News Source Type: news

Pfizer vaccine: Rates of deep vein thrombosis and thrombocytopenia after vaccine increase
AS MANY as 32 million people across the UK will be offered the COVID-19 vaccine in a bid to boost immunity ahead of winter. Although the Pfizer vaccine has proven highly effective at preventing serious illness from COVID-19, a recent study has suggested the jab could carry the rare risk of thrombocytopenia and deep vein thrombosis . (Source: Daily Express - Health)
Source: Daily Express - Health - August 7, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson ’s COVID-19 Shot Works Well Against Delta Variant, Study Finds
Johnson & Johnson’s COVID-19 vaccine helps prevent severe disease among those infected with the Delta variant, according to a trial involving almost 480,000 health workers in South Africa. The study, known as Sisonke, provides the first large-scale evidence that the J&J vaccine works against this dominant variant, according to trial co-lead Glenda Gray. It’s probably more protective against Delta than it was with the earlier beta strain, she said in a presentation Friday. The single-dose shot was 71% effective against hospitalization and as much as 96% effective against death, she said. It also demonstr...
Source: TIME: Health - August 6, 2021 Category: Consumer Health News Authors: Janice Kew and Antony Sguazzin / Bloomberg Tags: Uncategorized COVID-19 Source Type: news

NICE guideline - blood clotting condition associated with COVID-19 vaccination
NICE has published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations. (Source: NHS Networks)
Source: NHS Networks - August 2, 2021 Category: UK Health Source Type: news

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. (Source: Current Awaren...
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Rare blood clot cases not higher after AstraZeneca second dose: Study
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said. (Source: The Economic Times)
Source: The Economic Times - July 28, 2021 Category: Consumer Health News Source Type: news

Coronavirus vaccine - weekly summary of Yellow Card reporting (22 July), MHRA (updated 22nd July 2021)
This report (updated weekly) is based on analysis of data up to 14 July. It discusses overall safety and comments on specific reports, including thromboembolic events with thrombocytopenia, capillary leak syndrome, menstrual disorders, myocarditis/pericarditis, and others. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 26, 2021 Category: Consumer Health News Source Type: news

Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems
Organs from deceased donors who had received AstraZeneca's vaccine against SARS-CoV-2 may possibly prompt vaccine-induced thrombosis and thrombocytopenia in recipients, according to a new study.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 24, 2021 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news

Treatment for people suffering from Covid vaccine-related blood clots found
The researchers at the McMaster University recommend a combination of anti-clotting drugs and high doses of intravenous immunoglobulin to combat vaccine-induced immune thrombotic thrombocytopenia (VITT). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 1, 2021 Category: Pharmaceuticals Source Type: news

Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine
What is believed to be the first case of vaccine-induced thrombosis with thrombocytopenia after a messenger RNA COVID-19 vaccine has been reported.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 28, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Case reports thrombocytopenia with thrombosis following COVID-19 mRNA vaccine
(American College of Physicians) A single case reports thrombocytopenia with thrombosis syndrome (TTS) following the mRNA-1273 vaccine for COVID-19. Previously, it was hypothesized that adenoviral vector-based vaccines were the sole cause of TTS or vaccine-induced TTS (VITT). The case is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 28, 2021 Category: Infectious Diseases Source Type: news

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
FREDERICK, Md., June 16, 2021 -- (Healthcare Sales & Marketing Network) -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical... Biopharmaceuticals, Venture Capital Veralox Therapeutics, 12-lipoxygenase, heparin-induced thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Thrombocytopenia and COVID-19 Severity and Outcome Thrombocytopenia and COVID-19 Severity and Outcome
This systematic review shows that thrombocytopenia is common in COVID-19, and is associated with COVID-19 severity and outcome.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mini bone marrow model predicts response to blood disorder treatment
(eLife) A new miniature 3D model of human bone marrow has been described today in the open-access eLife journal. The model may help clinicians predict which patients will benefit from a new therapy for blood platelet disorders, such as Inherited Thrombocytopenias -- a group of familial disorders that inhibit the production of platelets. It could also enable further study of these disorders and give scientists a new tool to test experimental treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news

Eltrombopag may be cost effective for thrombocytopenia and PGF post transplantation
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca's COVID-19 vaccine), EMA
Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 25, 2021 Category: Consumer Health News Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Statins side effects: Unusual bleeding from various body parts could be thrombocytopenia
STATINS side effects: Like all medicines, statins can cause side effects. But most people tolerate them well and do not have any problems. However, some do not and with low blood platelet count being a common side effect from the drug another more serious condition may develop causing unusual bleeding from various body parts. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2021 Category: Consumer Health News Source Type: news

Management of vaccine-induced thrombosis and thrombocytopenia, RCS
There are increasing reports of a rare adverse event of thrombosis and thrombocytopenia following the first dose of the AstraZeneca COVID-19 vaccine, a syndrome labelled vaccine-induced thrombotic thrombocytopenia syndrome (VITT). The colleges and surgical specialty associations have produced guidance on the features and management of VITT, taking into account vascular, gastrointestinal and neurosurgical considerations. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 14, 2021 Category: Consumer Health News Source Type: news

Canada reports 28 cases of rare blood clots following AstraZeneca vaccinations
After distributing more than 2.3 million AstraZeneca vaccine doses nationwide, public health officials have so far identified 28 suspected cases of a rare but serious condition called vaccine-induced thrombotic thrombocytopenia (VITT). (Source: CBC | Health)
Source: CBC | Health - May 13, 2021 Category: Consumer Health News Tags: News/Politics Source Type: news

Coronavirus live news: jabs like Pfizer and Moderna appear able to ‘neutralise’ Indian variant, says EMA
European medicines watchdog says there is‘promising evidence’ the vaccines work against variant first encountered in IndiaCovid pandemic was preventable, says WHO-commissioned reportChina has used pandemic to boost global image, report saysUK prime minister announces independent inquiry into Covid handlingSpike in India variant poses threat to UK reopening, scientists sayAustralia: fresh outbreak blamed on hotel quarantine leak4.49pmBSTCovid-related deaths in theUS have fallen to an average of around 600 per day — the lowest level in 10 months — with the number of lives lost dropping to single digit...
Source: Guardian Unlimited Science - May 12, 2021 Category: Science Authors: Mattha Busby (now); Tobi Thomas, Martin Belam and Martin Farrer (earlier) Tags: Coronavirus India UK news US news Brazil Science Americas World news Source Type: news

Guidance Issued for Managing CVST After COVID - 19 Vaccination
CVST with thrombocytopenia reported after COVID - 19 vaccine with adenoviral vector; management similar to heparin - induced thrombocytopenia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Infections, Internal Medicine, Emergency Medicine, Neurology, Nursing, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Coronavirus vaccine - summary of Yellow Card reporting (up to 28 April), MHRA
The overall case incidence of thromboembolic events with concurrent thrombocytopenia reported in recipients of the Covid-19 Vaccine AstraZeneca was 10.5 per million doses. There is now some evidence the rate is higher in females, although this is not seen across all age groups. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 10, 2021 Category: Consumer Health News Source Type: news

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 6, 2021 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Vaccination COVID-19 Coronavirus Disease 2019 Source Type: news

12 Cases of CVST Reported for Ad26.COV2.S Vaccine in the U.S.
TUESDAY, May 4, 2021 -- Twelve cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia have been reported following use of the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson& Johnson), which uses a human adenoviral vector,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2021 Category: Pharmaceuticals Source Type: news

MHRA reports latest Yellow Card reporting data for coronavirus vaccines, MHRA
Based on analysis of data up to 21 April, the overall case incidence of major thromboembolic events with concurrent thrombocytopenia reported in recipients of the Covid-19 Vaccine AstraZeneca was 9.3 per million doses (209 cases, including 84 of cerebral venous sinus thrombosis). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Emergency physicians first to safely treat vaccine-induced blood clot with heparin alternative
(American College of Emergency Physicians) A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2021 Category: International Medicine & Public Health Source Type: news

EARLY RELEASE: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 30, 2021 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Vaccination COVID-19 Coronavirus Disease 2019 Source Type: news

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 29, 2021 Category: American Health Tags: Advisory Committee on Immunization Practices (ACIP) MMWR Morbidity & Mortality Weekly Report COVID-19 Coronavirus Disease 2019 Source Type: news

Primary Care Management of Suspected Thromboembolism with Thrombocytopenia after COVID-19 Vaccination, RCGP
Serious thromboembolic events with concurrent thrombocytopenia have occurred very rarely following vaccination with AstraZeneca (AZ) COVID-19 vaccine. This includes venous thrombosis, sometimes involving unusual sites such as cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis, or arterial thrombosis, combined with thrombocytopenia. It is currently estimated that the overall incidence of CVST following the AZ vaccine is around 4 per million first doses administered. Suspected cases have been reported in patients of all ages and genders and currently, no specific predisposing factors have been identified. ...
Source: Current Awareness Service for Health (CASH) - April 26, 2021 Category: Consumer Health News Source Type: news

Are There Developmental Changes in Platelet Function for Children?
Discussion While most people realize that each stage of a child’s life is different, there are some areas that people do not realize are different. For example, there are many laboratory values which are different based on the age because there are developmental changes. Within the hematopoietic system there are many developmental changes that are common such as hemoglobin and hematocrit. Others are less well known such as children have quantitatively less fibrinogen, but the activity is the same as adult fibrinogen. Platelets are an important part of both the primary and secondary hemostasis processes. They develop ...
Source: PediatricEducation.org - April 26, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
NEW BRUNSWICK, N.J., April 23, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combin...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news